制药生产率差距--研发效率虽有短暂提高，但仍在逐步下降。

IF 6.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2024-09-05 DOI:10.1016/j.drudis.2024.104160

Kenneth D.S. Fernald, Philipp C. Förster, Eric Claassen, Linda H.M. van de Burgwal

{"title":"制药生产率差距--研发效率虽有短暂提高，但仍在逐步下降。","authors":"Kenneth D.S. Fernald, Philipp C. Förster, Eric Claassen, Linda H.M. van de Burgwal","doi":"10.1016/j.drudis.2024.104160","DOIUrl":null,"url":null,"abstract":"<div><p>Rising research and development costs, currently exceeding $3.5 billion per novel drug, reflect a five-decade decline in pharmaceutical R&D efficiency. While recent reports suggest a potential turnaround, this review offers a systems-level analysis to explore whether this marks a structural shift or transient reversal. We analyzed financial data from the 200 largest pharmaceutical firms, novel drug approvals, and more than 80 000 clinical trials between 2012 and 2023. Our analysis revealed that despite recent stabilization, the pharmaceutical industry continues to face challenges, particularly due to elevated late-stage clinical attrition, suggesting that a sustained turnaround in R&D efficiency remains elusive.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 11","pages":"Article 104160"},"PeriodicalIF":6.5000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S135964462400285X/pdfft?md5=6183df0c7f5f5378cd212c69c2ae5b5f&pid=1-s2.0-S135964462400285X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements\",\"authors\":\"Kenneth D.S. Fernald, Philipp C. Förster, Eric Claassen, Linda H.M. van de Burgwal\",\"doi\":\"10.1016/j.drudis.2024.104160\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Rising research and development costs, currently exceeding $3.5 billion per novel drug, reflect a five-decade decline in pharmaceutical R&D efficiency. While recent reports suggest a potential turnaround, this review offers a systems-level analysis to explore whether this marks a structural shift or transient reversal. We analyzed financial data from the 200 largest pharmaceutical firms, novel drug approvals, and more than 80 000 clinical trials between 2012 and 2023. Our analysis revealed that despite recent stabilization, the pharmaceutical industry continues to face challenges, particularly due to elevated late-stage clinical attrition, suggesting that a sustained turnaround in R&D efficiency remains elusive.</p></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"29 11\",\"pages\":\"Article 104160\"},\"PeriodicalIF\":6.5000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S135964462400285X/pdfft?md5=6183df0c7f5f5378cd212c69c2ae5b5f&pid=1-s2.0-S135964462400285X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S135964462400285X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S135964462400285X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目前，每种新药的研发成本超过 35 亿美元，不断攀升的研发成本反映了制药研发效率长达五十年的下降。虽然最近的报告显示可能会出现转机，但本综述提供了系统层面的分析，以探讨这是结构性转变还是短暂的逆转。我们分析了 200 家最大制药公司的财务数据、新药批准情况以及 2012 年至 2023 年间的 80000 多项临床试验。我们的分析表明，尽管医药行业近期趋于稳定，但仍面临着挑战，尤其是由于后期临床损耗的增加，这表明研发效率的持续好转仍遥遥无期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements

Rising research and development costs, currently exceeding $3.5 billion per novel drug, reflect a five-decade decline in pharmaceutical R&D efficiency. While recent reports suggest a potential turnaround, this review offers a systems-level analysis to explore whether this marks a structural shift or transient reversal. We analyzed financial data from the 200 largest pharmaceutical firms, novel drug approvals, and more than 80 000 clinical trials between 2012 and 2023. Our analysis revealed that despite recent stabilization, the pharmaceutical industry continues to face challenges, particularly due to elevated late-stage clinical attrition, suggesting that a sustained turnaround in R&D efficiency remains elusive.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.